Estimation of the antirelapse efficacy of tafenoquine, using plasmodium vivax genotyping

Journal of Infectious Diseases

Volumn 212, Issue 11, 2015, Pages 794-799

  Beck, Hans Peter ^a,b   Wampfler, Rahel ^a,b   Carter, Nick ^d   Koh, Gavin ^d   Osorio, Lyda ^e   Rueangweerayut, Ronnatrai ^f   Krudsood, Srivcha ^g   Lacerda, Marcus V ^h   Llanos Cuentas, Alejandro ^i,j   Duparc, Stephan ^c   Rubio, Justin P ^d   Green, Justin A ^d  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Medicines for Malaria Venture   (Switzerland)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSIDAD DEL VALLE   (Colombia)

^f MAE SOT GENERAL HOSPITAL   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h Instituto de Pequisa Clínicas Carlos Borborema   (Brazil)

ⁱ INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^j UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

more..

Author keywords

Antihypnozoite; Efficacy; Genotyping; Plasmodium vivax; Tafenoquine

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CHLOROQUINE; CIRCUMSPOROZOITE PROTEIN; GENOMIC DNA; PLACEBO; PRIMAQUINE; TAFENOQUINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT;

ADOLESCENT; ARTICLE; BRAZIL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GENE AMPLIFICATION; GENOTYPE; GIEMSA STAIN; HAPLOTYPE; HUMAN; INDIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEROZOITE; MONOTHERAPY; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); PARASITE CLEARANCE; PERU; PHASE 2 CLINICAL TRIAL; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SINGLE DRUG DOSE; THAILAND; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GENETICS; MALARIA, VIVAX; SECONDARY PREVENTION;

AMINOQUINOLINES; ANTIMALARIALS; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; PRIMAQUINE; SECONDARY PREVENTION;

EID: 84958591009     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv508     Document Type: Article

References (14)

1. Battle KE, Gething PW, Elyazar IR, et al. The global public health significance of Plasmodium vivax. Adv Parasitol 2012; 80:1-111
2. Campo B, Vandal O, Wesche DL, Burrows JN. Killing the hypnozoite-drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health 2015; 109:107-22
3. Koepfli C, Mueller I, Marfurt J, et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 2009; 199:1074-80
4. Koepfli C, Ross A, Kiniboro B, et al. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis 2011; 5:e1424
5. Lin JT, Hathaway NJ, Saunders DL, et al. Using amplicon deep sequencing to detect genetic signatures of Plasmodium vivax relapse. J Infect Dis 2015; 212:999-1008
6. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049-58
7. Mendes C, Dias F, Figueiredo J, et al. Duffy negative antigen is no longer a barrier to Plasmodium vivax-molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis 2011; 5:e1192
8. Ord RL, Tami A, Sutherland CJ. ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency. PLoS One 2008; 3:e3366
9. Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013; 369:1381-2
10. Batista CL, Barbosa S, Da Silva Bastos M, Viana SA, Ferreira MU. Genetic diversity of Plasmodium vivax over time and space: a community-based study in rural Amazonia. Parasitology 2014:1-11
11. Thanapongpichat S, McGready R, Luxemburger C, et al. Microsatellite genotyping of Plasmodium vivax infections and their relapses in pregnant and non-pregnant patients on the Thai-Myanmar border. Malar J 2013; 12:275
12. Van den Eede P, Van der Auwera G, Delgado C, et al. Multilocus genotyping reveals high heterogeneity and strong local population structure of the Plasmodium vivax population in the Peruvian Amazon. Malar J 2010; 9:151
13. Dhangadamajhi G, Rout BK, Kar SK, Ranjit MR. Genetic diversity of Plasmodium vivax in a hyperendemic area predominated by Plasmodium falciparum; a preliminary study. Trop Biomed 2010; 27:578-84
14. Betuela I, Rosanas-Urgell A, Kiniboro B, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis 2012; 206:1771-80